Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 51 min ago
Peer-reviewedCC BY 4.0Frontiers in Oncology

Application of antibody-drug conjugates in colorectal cancer

Abstract

Colorectal cancer (CRC) remains a leading cause of cancer incidence and mortality worldwide, and metastatic disease responds poorly to conventional surgery, chemotherapy, and targeted therapy. Antibody-drug conjugates (ADCs) link monoclonal antibodies to cytotoxic payloads through chemical linkers, enabling antigen-specific delivery, intracellular payload release, bystander killing, and Fc-mediated immune effects. ADC efficacy and safety depend on target antigen selection, antibody design, payload choice, linker stability, and internalization efficiency. This narrative review, based on literature and trial data available up to February 2026, summarizes the CRC treatment landscape, ADC mechanisms and component optimization, and clinical progress of ADCs targeting HER2, HER3, TROP-2, CEACAM5, and c-MET. No ADC has been approved specifically for CRC; trastuzumab deruxtecan has tumor-agnostic accelerated approval for HER2 IHC 3+ solid tumors and may cover eligible patients with metastatic CRC. Early trials show promising activity but substantial hematologic, gastrointestinal, hepatic, and interstitial lung disease toxicity, reflecting a narrow therapeutic window. We discuss challenges including target specificity, off-target toxicity, drug resistance, and linker stability, and outline future directions such as probody-drug conjugates, bispecific and dual-payload ADCs, novel payloads, and bioorthogonal linkers to support precision therapy for CRC.

Related

  1. Antibody–drug conjugates in colorectal cancer: target biology, resistance, and the clinical-trial landscape
    Chaofan Chen, Luming Guo, Xu Han +1
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  2. Efficacy and safety of antibody-drug conjugates in advanced small cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. Efficacy and safety of antibody-drug conjugates in pretreated HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials
    Fen Liu, Yong Pan, Jinlan Li +2
    Frontiers in pharmacologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  4. Emerging antibody–drug conjugates in lung cancer: highlights from the 2026 ASCO Annual Meeting
    Xiaolei Wang, Jiayuan Miao, Yuxuan Bao +4
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  5. Combination of antibody–drug conjugates with immunotherapy: a new paradigm in cancer treatment
    Yongli Lai, Ruyu Qin, Zhaidong Liu
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
BibTeX
@article{cai2026application,
  title = {{Application of antibody-drug conjugates in colorectal cancer}},
  author = {Huazhong Cai and Jingzhe Li and Qiang Cai and Ying Liu and Pan Huang},
  journal = {Frontiers in Oncology},
  year = {2026},
  month = nov,
  doi = {10.3389/fonc.2026.2011302},
  url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.2011302},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Application of antibody-drug conjugates in colorectal cancer
AU  - Huazhong Cai
AU  - Jingzhe Li
AU  - Qiang Cai
AU  - Ying Liu
AU  - Pan Huang
PY  - 2026
DA  - 2026/11/13
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.2011302
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2026.2011302
AB  - Colorectal cancer (CRC) remains a leading cause of cancer incidence and mortality worldwide, and metastatic disease responds poorly to conventional surgery, chemotherapy, and targeted therapy. Antibody-drug conjugates (ADCs) link monoclonal antibodies to cytotoxic payloads through chemical linkers, enabling antigen-specific delivery, intracellular payload release, bystander killing, and Fc-mediated immune effects. ADC efficacy and safety depend on target antigen selection, antibody design, payload choice, linker stability, and internalization efficiency. This narrative review, based on literature and trial data available up to February 2026, summarizes the CRC treatment landscape, ADC mechanisms and component optimization, and clinical progress of ADCs targeting HER2, HER3, TROP-2, CEACAM5, and c-MET. No ADC has been approved specifically for CRC; trastuzumab deruxtecan has tumor-agnostic accelerated approval for HER2 IHC 3+ solid tumors and may cover eligible patients with metastatic CRC. Early trials show promising activity but substantial hematologic, gastrointestinal, hepatic, and interstitial lung disease toxicity, reflecting a narrow therapeutic window. We discuss challenges including target specificity, off-target toxicity, drug resistance, and linker stability, and outline future directions such as probody-drug conjugates, bispecific and dual-payload ADCs, novel payloads, and bioorthogonal linkers to support precision therapy for CRC.
SN  - 2234-943X
ER  -